INTRODUCTION
============

Lung cancer represents the leading cause of cancer deaths in Korea \[[@B1]\] and Western countries \[[@B2]\]. Non-small cell lung cancer (NSCLC) accounts for approximately 75% of lung cancers \[[@B3]\]. About 50% of NSCLC patients are initially diagnosed with advanced or metastatic disease, and the treatment of choice is palliative chemotherapy. Platinum doublets have superior treatment outcomes over single-agent chemotherapy, and are regarded as standard first-line treatment in advanced NSCLC \[[@B4]-[@B6]\]. Although lung cancer has a dismal prognosis, a substantial percentage of patients progress after first-line treatment with good performance status (PS) and adequate organ function. Further salvage treatment should be considered \[[@B3]\].

After docetaxel was approved as a second-line therapy in patients with advanced NSCLC \[[@B7]\], several other drugs were evaluated for their efficacy and safety as potential substitutes. Pemetrexed (Alimta®; Eli Lilly and Company, Indianapolis, IN, USA) is a multi-targeted anti-folate compound. A randomized phase III trial demonstrated non-inferiority of pemetrexed to docetaxel with fewer grade 3 or 4 toxicities \[[@B8]\]. Erlotinib (Tarceva®; Genentech, San Francisco, CA, USA and OSI Pharmaceuticals, Melville, NY, USA) is an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). A phase III BR.21 study \[[@B9]\] compared erlotinib with best supportive care (BSC) in 731 advanced NSCLC patients. A higher progression-free survival (PFS) and overall survival (OS) was shown in patients treated with erlotinib compared to BSC. Gefitinib (Iressa®; AstraZeneca, Wilmington, DE, USA) is another EGFR TKI that was safe and efficacious at a dose of 250 mg/day in a large-scale phase II trial in patients with advanced NSCLC who had undergone a previous treatment regimen \[[@B10]\]. Although a phase III study by Thatcher et al. \[[@B11]\] failed to demonstrate the superiority of gefitinib over BSC, the subsequent phase III IRESSA NSCLC Trial Evaluating Response and Survival against Taxotere (INTEREST) study \[[@B12]\], which compared gefitinib with docetaxel, reported that gefitinib had similar clinical outcomes, with better tolerability and more convenient administration than docetaxel in previously treated patients with advanced or metastatic NSCLC who had failed platinum-based chemotherapy. Although these drugs were approved and have been commonly used as second-line or salvage therapy in patients with NSCLC, data directly comparing pemetrexed and EGFR TKIs are limited \[[@B13]\]. Therefore, this study compared the efficacy and safety of three agents in previously treated patients with NSCLC.

METHODS
=======

Patients
--------

Previously treated patients with advanced NSCLC at a single institution (Gachon University Gil Hospital, Incheon, Korea) were analyzed retrospectively. Eligibility for the study included the following: histologically or cytologically confirmed NSCLC; ≥ 18 years of age with advanced (stage IIIB or IV) or recurrence at initial diagnosis; Eastern Cooperative Oncology Group (ECOG) PS 0 to 2; at least one measurable lesion; previous chemotherapy without exposure to the three study drugs; and adequate marrow and organ function. This study was reviewed and approved by the Institutional Review Board of Gachon University Gil Hospital.

Treatment
---------

Patients in the pemetrexed group were administered 500 mg/m^2^ of pemetrexed mixed with 100 mL of normal saline as a 10-minute intravenous infusion on day 1 every 3 weeks. Patients in the gefitinib group received gefitinib (250 mg per os \[PO\] daily), and patients in the erlotinib group received erlotinib (150 mg PO daily). Cycles were repeated until disease progression, unacceptable toxicity, or the patient declined further treatment. Patients in the pemetrexed group were instructed to take folic acid (1 mg orally daily) from day 7 of the first cycle to the end of pemetrexed treatment and a vitamin B12 (1,000 µg) was injected intramuscularly 1 week before the first dose of pemetrexed in the first cycle, and then every three chemotherapy cycles. A delay of the next cycle for up to 21 days was permitted. For erlotinib, one dose reduction per patient from 150 to 100 mg was permitted in the case of grade 3 or 4 diarrhea or skin reactions.

Evaluation of the tumor response and toxicity
---------------------------------------------

Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 \[[@B14]\] was used to evaluate the response. Chest computed tomography (CT) and other modalities to evaluate measurable or evaluable lesions were performed within 2 weeks before treatment initiation and every two cycles of pemetrexed or every 2 months of EGFR TKI therapy. Common Terminology Criteria for Adverse Event (CTCAE) version 3.0 \[[@B15]\] was used to identify adverse events.

Statistical consideration
-------------------------

We analyzed the PFS, response rates (RRs), disease control rates (DCRs; the sum of complete response, partial response, and stable disease, as defined by RECIST), safety profiles of each group, and PFS according to clinical characteristics.

Fisher\'s exact test was applied to compare response rates and toxic effects between treatments. The Kaplan-Meier method was used for survival analysis. The log-rank test was performed for univariate analysis of survival, and variables showing an association with survival on univariate analysis with *p* \< 0.1 were included in multivariate analysis using Cox proportional hazard regression models.

RESULTS
=======

Patient characteristics
-----------------------

Between September 2005 and August 2008, 57 patients received pemetrexed (n = 20), gefitinib (n = 20), or erlotinib (n = 17). The patient characteristics were balanced, except for the number of cigarette smokers, which was more common in the pemetrexed group ([Table 1](#T1){ref-type="table"}). The median number of chemotherapy cycles administered was 2 (range, 1 to 4) in the pemetrexed group. The median duration of treatment was 3.2 months (range, 0.8 to 18.3) and 4.4 months (range, 0.5 to 17.5) for patients receiving gefitinib and erlotinib, respectively.

Evaluation of tumor response and survival
-----------------------------------------

Two of 57 patients (one each for pemetrexed and gefitinib) were not evaluated for treatment response. The objective RR was 5.3% for pemetrexed, 25% for gefitinib, and 12.5% for erlotinib (*p* = 0.22). The DCR of pemetrexed, gefitinib, and erlotinib was 5.3%, 40.0%, and 50.0%, respectively (*p* \< 0.01). No patient in the pemetrexed group maintained a partial response (PR) or stable disease defined by the RECIST criteria for at least 1 month, except for one patient with a PR.

The median duration of follow-up was 12.1 months. Fifty-two patients had disease progression (20 in the pemetrexed, 19 in the gefitinib, and 13 in the erlotinib groups) and 20 patients died (8 in the pemetrexed, 7 in the gefitinib, and 5 in the erlotinib groups). The median PFS in the pemetrexed, gefitinib, and erlotinib groups was 1.7, 3.5, and 4.4 months, respectively (*p* \< 0.01). The median OS was 5.6, 21.8, and 21.5 months in the respective groups (*p* = 0.04). [Fig. 1](#F1){ref-type="fig"} shows the Kaplan-Meier curves for PFS and OS.

Based on univariate analysis, patients administered an EGFR TKI, female, and no cigarette smoking had a significantly better PFS. Multivariate analysis revealed that only the use of an EGFR TKI contributed independently to prolonging the PFS ([Table 2](#T2){ref-type="table"}). There was no significant difference in the RR (*p* = 0.43), DCR (*p* = 0.74), and PFS (*p* = 0.43) between patients treated with gefitinib and erlotinib.

The DCRs of patients treated with gefitinib or erlotinib were also higher among patients with non-squamous carcinoma (*p* \< 0.01), male gender (*p* = 0.02), cigarette smokers (*p* = 0.02), patients with a good performance status (0 or 1; *p* \< 0.01), patients with a good prior response (*p* \< 0.01), and patients ≥ 60 years of age (*p* = 0.03) than patients treated with pemetrexed. Analysis of the PFS according to clinical factors is summarized in [Table 3](#T3){ref-type="table"}.

Twelve of 20 patients in the gefitinib group and 10 of 17 patients in the erlotinib group received subsequent pemetrexed as a salvage treatment after progression. Three of these 22 patients achieved a partial response (PR); however, the response lasted for less than 1 month. In the pemetrexed group, 16 of 20 patients received gefitinib (2 of 16) or erlotinib (14 of 16) as salvage therapy after progression; only one patient had a PR with a duration of response of 4.5 months.

Toxicity
--------

All treated patients (n = 57) were assessable for toxicity. Of the erlotinib group, 11.7% required a dose reduction because of drug-related toxic effects. The median number of chemotherapy cycles administered was 2 (range, 1 to 9) in the pemetrexed group. The median duration of treatment was 3.2 months for the pemetrexed group, and 4.4 months for the patients receiving gefitinib and erlotinib. One patient in the gefitinib group and three patients in the erlotinib group discontinued EGFR TKI because of severe or prolonged non-hematologic toxicity (one patient for diarrhea in the gefitinib group and three patients for skin rashes in the erlotinib group). The frequently reported toxicities in the gefitinib and erlotinib groups were skin disorders (rash, dry skin, pruritus, and acne), diarrhea, and anorexia. The toxicity profiles are shown in [Table 4](#T4){ref-type="table"}.

DISCUSSION
==========

In contrast to pemetrexed \[[@B8]\] and gefitinib \[[@B12]\], which were not inferior to docetaxel in a large phase III trial, there are no reported clinical trials that directly compare erlotinib with docetaxel. Instead, erlotinib was approved as a second- or third-line agent based on the result of the BR21 study \[[@B9]\] comparing erlotinib with placebo. In BR21, the median OS and median PFS improved significantly with erlotinib (6.7 vs. 4.7 months for OS; *p* = 0.002 and 2.2 vs. 1.8 months for PFS; *p* \< 0.001). In our study, erlotinib was efficacious and safe, comparable to the other EGFR TKI, gefitinib. There was no difference in the baseline characteristics, RRs, DCRs, or survivals between the gefitinib and erlotinib arms.

No prospective trials have reported the results of a comparison between pemetrexed and EGFR TKIs after the failure of first-line chemotherapy. Although treatment with gefitinib or erlotinib was associated with longer survival in our study, the result should be interpreted cautiously because our study has several limitations. The numbers of patients in each group were not large enough for a conclusive analysis and the baseline patient characteristics were not stratified homogeneously in this study. The numbers of male patients, smokers, and squamous cell carcinoma were higher in the pemetrexed arm than in the other groups, although the differences were not significant, except for smoking. Many previous studies reported good efficacy and improved survival of both EGFR TKIs for ethnic Asians, women, non-smokers, and non-squamous histology \[[@B9]-[@B11],[@B16],[@B17]\]. Based on these results, the Korean Health Insurance Review & Assessment Service accepted the use of EGFR TKIs as second-line treatment if at least two of the following three are satisfied: female gender, adenocarcinoma, and non-smoker \[[@B18]\]. As this was a retrospective study that analyzed previously treated NSCLC patients who underwent salvage chemotherapy in clinical practice without specific standards for the use of one of the three drugs, the criteria of the Korean Health Insurance Service for EGFR TKIs probably affected the heterogeneous patient characteristics because TKIs are more convenient as they do not need intravenous administration, unlike pemetrexed.

The larger number of patients with squamous histology might also be a disadvantage for the pemetrexed arm. Pemetrexed shows higher efficacy in advanced NSCLC with non-squamous histology. In a prospective phase III study \[[@B19]\], cisplatin with pemetrexed conferred similar efficacy with better tolerability than cisplatin with gemcitabine as first-line chemotherapy in advanced NSCLC. In this large-scale (1,725 patients) study, the OS of the patients with adenocarcinoma or large cell carcinoma histology on cisplatin in the pemetrexed arm was significantly longer than the OS of patients with the same histology on cisplatin with gemcitabine (for adenocarcinoma, median 12.6 vs. 10.9 months, *p* = 0.03; for large cell carcinoma, median 10.4 vs. 6.7 months, *p* = 0.03). By contrast, for patients with squamous cell carcinoma, cisplatin with pemetrexed had a slightly shorter OS than cisplatin with gemcitabine (median 9.4 vs. 10.8 months, respectively, *p* = 0.05). This difference in the clinical characteristics probably contributed to the substantially poorer tumor response and disease control in this study (Eighteen of 19 evaluable patients had progressive disease as their best response after pemetrexed), compared to the previous study \[[@B8]\]. A hypothesis generated by this study is \"baseline clinicopathological characteristics have substantial effects on clinical outcomes\" rather than \"EGFR TKIs are superior to pemetrexed.\"

Of the 41 patients with non-squamous carcinoma, a longer PFS in patients treated with gefitinib or erlotinib than pemetrexed (*p* \< 0.01) was observed. This may reflect 4 of 11 (36.4%) \'non-small cell carcinomas\' in which further detailed pathology could not be determined. In the patients with squamous carcinoma, the outcomes were universally poor, and no superiority of TKIs was shown. Superiority of TKIs was also observed in patients with a good PS, a good prior response, male gender, or cigarette smokers, although the interpretation should be made with caution because the results of univariate or multivariate analysis have limitations with a small sample size.

Since no head-to-head comparison with docetaxel exists, second-line treatment of advanced NSCLC with erlotinib remains controversial in the UK \[[@B13]\]. The results are pending for a randomized trial with erlotinib as second-line treatment versus docetaxel or pemetrexed (Tarceva in Treatment of Advanced NSCLC \[TITAN study\]). The accumulation of clinical data and the application of genetic mutational analysis will enable more efficacious and tailored therapy in patients with advanced NSCLC.

In summary, this retrospective study showed that both oral EGFR TKIs had comparable efficacy with manageable toxicities. The comparison between pemetrexed and the EGFR TKIs was limited by the heterogeneous baseline patient characteristics. The superior PFS and OS of the patients with EGFR TKIs with more favorable clinical factors compared to those of the patients with pemetrexed reflects the effect of baseline characteristics and underlines the necessity of patient selection according to baseline clinicopathological factors for optimal treatment in advanced NSCLC.
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Univariate and multivariate analyses of the progression-free survival
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HR, hazard ratio; CI, confidence interval; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; Sq., squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease.
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Analysis of the progression-free survival according to clinical factors
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EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease.
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Toxicity profiles
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^a^According to the National Cancer Institute-Common Toxicity Criteria, version 3.0.
